Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Studying Interventions for Managing Patients With Chronic Myeloid Leukemia (CML)in Chronic Phase: The 5-Year Prospective Cohort Study (SIMPLICITY)

Trial Profile

Studying Interventions for Managing Patients With Chronic Myeloid Leukemia (CML)in Chronic Phase: The 5-Year Prospective Cohort Study (SIMPLICITY)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Jan 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dasatinib (Primary) ; Imatinib (Primary) ; Nilotinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SIMPLICITY
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 13 Dec 2022 Results (At data cutoff January 28, 2020, n=810 US patients ), presented at the 64th American Society of Hematology Annual Meeting and Exposition
    • 13 Dec 2022 Results of Five-Year Overall Survival Analysis Using First- and Second-Generation Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase presented at the 64th American Society of Hematology Annual Meeting and Exposition
    • 28 Jun 2022 Status changed from active, no longer recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top